SEC Info℠

Home

Search

My Interests

Help

Sign In

Please Sign In

Curaxis Pharmaceutical Corp – IPO: ‘S-1/A’ on 10/13/05 – EX-10.15

On:  Thursday, 10/13/05, at 4:17pm ET   ·   Accession #:  1193125-5-200972   ·   File #:  333-128193

Previous ‘S-1’:  ‘S-1’ on 9/9/05   ·   Next:  ‘S-1/A’ on 10/28/05   ·   Latest:  ‘S-1/A’ on 12/8/05

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

 Text Wildcards:  ? (any letter/digit),  * (many).  Search Logic:  for Documents:  & (and),  | (or);  for Text:  | (anywhere),  "(&)" (near).  Details... 

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

10/13/05  Curaxis Pharmaceutical Corp       S-1/A                  9:1.9M                                   RR Donnelley/FA

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Amendment No. 1 to Form S-1                         HTML   1.21M 
 2: EX-3.1      Amended and Restated Certificate of Incorporation   HTML     68K 
 3: EX-3.4      Amended and Restated By-Laws                        HTML     95K 
 7: EX-10.14    Non-Employee Director Compensation Summary          HTML      9K 
 8: EX-10.15    Executive Officer Compensation Summary              HTML     10K 
 4: EX-10.3     2005 Stock Incentive Plan                           HTML     54K 
 5: EX-10.4     Form of Incentive Stock Option Agreement            HTML     28K 
 6: EX-10.5     Form of Nonstatutory Stock Option Agreement         HTML     29K 
 9: EX-23.1     Consent of Pricewaterhousecoopers LLP               HTML      6K 

Exhibit 10.15

Executive Officer Compensation Summary

Voyager Pharmaceutical Corporation’s (the “Company’s”) executive officers consist of: (i) Patrick S. Smith, President and Chief Executive Officer; (ii) Richard L. Bowen, M.D., Chairman of the Board and Chief Scientific Officer; (iii) David J. Corcoran, Executive Vice President and Chief Financial Officer; (iv) Sheldon Goldberg, Senior Vice President of Corporate Development; (v) Michael J. Giannini, Vice President of Business Operations; (vi) Timothy J. Creech, Vice President of Finance and Chief Accounting Officer; (vii) Steven J. Fiander, Vice President of Sales and Marketing; (viii) Maynard E. Lichty, Vice President of Manufacturing and Technical Operations; (ix) Laurence C. Tusick, Vice President of Sales and Marketing; and (x) Barbra J. LaPlante, Vice President of Clinical Operations.

The compensation structure for executive officers of the Company currently consists of two components: base salary and stock options. The Company does not have employment arrangements with any of its executive officers, except for Sheldon Goldberg and Michael J. Giannini.

The Company’s board of directors approved the following fiscal year 2005 base salaries for the executive officers named below: